Breyanzi (lisocabtagene maraleucel) - BMS
avipendekin pegol (NKTR-255) - Nektar Therapeutics
cyclophosphamide - Generic mfg.
fludarabine IV - Generic mfg.
NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Sep 22, 2026 - P1 | N=27 | Completed | Sponsor: Fred Hutchinson Cancer Center | Active, not recruiting ➔ Completed 
Trial completion • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD19
http://clinicaltrials.gov/ct2/show/NCT05359211
 
Sep 22, 2026
 
Prev Next